First of all, alisertib – a specific Aurora kinase A inhibitor currently being evaluated in clinical trials in various neoplastic conditions, including acute myeloid leukemia [33–35] demonstrated very good preclinical activity when we tested it in HMC-1 cells and in neoplastic MCs from MCL patients. This evidence concerns the gene AURKA and acute myeloid leukemia.